Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients

Antimicrob Agents Chemother. 2011 Apr;55(4):1549-55. doi: 10.1128/AAC.00910-10. Epub 2011 Jan 31.

Abstract

Studies were conducted to determine if there is a mechanistic basis for reports of suboptimal virologic responses and concerns regarding the safety of regimens containing the combination of tenofovir (TFV) disoproxil fumarate (TDF) and didanosine (ddI) by assessing the pharmacokinetic consequences of coadministration of these drugs on intracellular nucleotides. This was a prospective and longitudinal study in HIV-1-infected patients of adding either TDF or ddI to a stable antiretroviral regimen containing the other drug. Intracellular concentrations of the nucleotide analogs TFV diphosphate (TFV-DP) and ddATP and the endogenous purine nucleotides dATP and 2'-dGTP in peripheral blood mononuclear cells were measured. A total of 16 patients were enrolled into the two study arms and a study extension. Intracellular TFV-DP concentrations (median, 120 fmol/10(6) cells) and ddATP concentrations (range, 1.50 to 7.54 fmol/10(6) cells in two patients) were unaffected following addition of ddI or TDF to a stable regimen containing the other drug. While coadministration of ddI and TDF for 4 weeks did not appear to impact dATP or dGTP concentrations, cross-sectional analysis suggested that extended therapy with ddI-containing regimens, irrespective of TDF coadministration, may decrease dATP and ddATP concentrations. Addition of TDF or ddI to a stable regimen including the other drug, in the context of ddI dose reduction, did not adversely affect the concentration of dATP, dGTP, TFV-DP, or ddATP. The association between longer-term ddI therapy and reduced intracellular nucleotide concentrations and this observation's implication for the efficacy and toxicity of ddI-containing regimens deserve further study.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / pharmacokinetics
  • Adenine / therapeutic use
  • Adult
  • Aged
  • Anti-HIV Agents / pharmacokinetics*
  • Anti-HIV Agents / therapeutic use*
  • Chromatography, Liquid
  • Deoxyadenine Nucleotides / blood
  • Deoxyguanine Nucleotides / blood
  • Didanosine / pharmacokinetics*
  • Didanosine / therapeutic use*
  • Dideoxynucleotides / blood
  • Female
  • HIV Infections / blood
  • HIV Infections / drug therapy*
  • Humans
  • Male
  • Middle Aged
  • Nucleotides / blood*
  • Organophosphonates / pharmacokinetics*
  • Organophosphonates / therapeutic use*
  • Tandem Mass Spectrometry
  • Tenofovir
  • Young Adult

Substances

  • Anti-HIV Agents
  • Deoxyadenine Nucleotides
  • Deoxyguanine Nucleotides
  • Dideoxynucleotides
  • Nucleotides
  • Organophosphonates
  • 2',3'-dideoxyadenosine triphosphate
  • deoxyguanosine triphosphate
  • Tenofovir
  • Adenine
  • Didanosine
  • 2'-deoxyadenosine triphosphate